Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

Nkarta, Inc. (NKTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13G/A WASATCH ADVISORS LP reports a 3.8% stake in Nkarta Inc.
08/23/2023 4 Shook David (Chief Medical Officer) has filed a Form 4 on Nkarta, Inc.
Txns: Sold 1,331 shares @ $1.83, valued at $2.4k
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights • NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine lymphodepletion regimen • NKX019 clinical data presented at EHA 2023 and ICML 2023 meetings • Clinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024 • Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations into 2025"
07/05/2023 4 Levin Alyssa (See Remarks) has filed a Form 4 on Nkarta, Inc.
Txns: Granted 442,400 options to buy @ $2.19, valued at $968.9k
07/05/2023 3 Levin Alyssa (See Remarks) has filed a Form 3 on Nkarta, Inc.
07/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Nkarta Appoints Alyssa Levin Chief Financial and Business Officer"
07/05/2023 4 Shook David (Chief Medical Officer) has filed a Form 4 on Nkarta, Inc.
Txns: Granted 208,000 options to buy @ $2.19, valued at $455.5k
06/09/2023 4 George Simeon (Director) has filed a Form 4 on Nkarta, Inc.
Txns: Granted 22,500 options to buy @ $4.86, valued at $109.4k
06/09/2023 4 Behbahani Ali (Director) has filed a Form 4 on Nkarta, Inc.
Txns: Granted 22,500 options to buy @ $4.86, valued at $109.4k
06/09/2023 4 RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Nkarta, Inc.
Txns: Granted 22,500 options to buy @ $4.86, valued at $109.4k
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENTOFRESTATED CERTIFICATE OF INCORPORATIONOF"
06/09/2023 4 Thedinga Angela (Director) has filed a Form 4 on Nkarta, Inc.
Txns: Granted 22,500 options to buy @ $4.86, valued at $109.4k
06/09/2023 4 PATTERSON LEONE D (Director) has filed a Form 4 on Nkarta, Inc.
Txns: Granted 22,500 options to buy @ $4.86, valued at $109.4k
06/09/2023 4 Dybbs Michael (Director) has filed a Form 4 on Nkarta, Inc.
Txns: Granted 22,500 options to buy @ $4.86, valued at $109.4k
06/09/2023 4 Azzam Fouad Oscar (Director) has filed a Form 4 on Nkarta, Inc.
Txns: Granted 22,500 options to buy @ $4.86, valued at $109.4k
06/09/2023 4 Scheiner Zachary (Director) has filed a Form 4 on Nkarta, Inc.
Txns: Granted 22,500 options to buy @ $4.86, valued at $109.4k
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023 • Cash and cash equivalents of $332.1 million on March 31, 2023 • Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., May 11, 2023 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies, today reported financial results for the first quarter ended March 31, 2023. “Nkarta remains focused on the potential of donor-derived CAR NK cell products to broaden access to the transformative power of cell therapy for patients,” said Paul J. Hastings, CEO and President of Nkarta. &#x..."
05/10/2023 SC 13G/A WASATCH ADVISORS LP reports a 10.1% stake in Nkarta Inc.
05/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/24/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
04/24/2023 ARS Form ARS - Annual Report to Security Holders:
04/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/17/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Quarterly results
Docs: "Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights • Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 • 2022 year-end cash and cash equivalents of $354.9 million • Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., March 16, 2023 -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2022. “Clinical data from our co-lead pipeline candidates have highlighted the promise of our allogeneic NK cell therapy technology to lead the next wave of cell therapy,” said Paul J. Hastings, President and C..."
02/14/2023 SC 13D/A Samsara BioCapital, L.P. reports a 5.9% stake in Nkarta, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/09/2023 SC 13G WASATCH ADVISORS INC reports a 5.6% stake in Nkarta Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy